Peter J. Ell

Active Medicine (United Kingdom) — United Kingdom

Medicine · Health Sciences

47h-index8.9kcitations299works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(86), Cardiac Imaging and Diagnostics(40), Schizophrenia research and treatment(36), Advanced MRI Techniques and Applications(31), Radiopharmaceutical Chemistry and Applications(31)

Publications298 total

Supplementary Table 1 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Data from Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
2023Open Access
Data from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Supplementary Table 1 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
CCR Translation for This Article from Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
2023Open Access
Supplementary Data from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Appendix from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
CCR Translation for This Article from Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
2023Open Access
Supplementary Figure 2 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Appendix from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figure 1 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Supplementary Data from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figure 1 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Data from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figure 2 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
2023Open Access
Data from Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
2023Open Access
Early diagnosis and space occupying disease an ever increasing complex problem.
Acta Médica Portuguesa·2022· 2 citedOpen Access
Breaking an unhelpful circle, where innovation and regularia delay clinical practice for patient benefit
European Journal of Nuclear Medicine and Molecular Imaging·2019· 2 citedOpen Access
A fresh breeze sweeps through nuclear medicine 2018
Clinical and Translational Imaging·2018· 1 citedOpen Access
Quantitative phaseanalysis intheassessmentof coronaryarterydisease
2017
page 1 of 15Next →

Frequent Co-authors

Durval C. Costa(23), Lyn S. Pilowsky(22), Robert Kerwin(13), Rachel S. Mulligan(9), Geraldo F. Busatto(8), Paul D. Acton(6), Kjell Erlandsson(6), N. P. L. G. Verhoeff(5), Rodrigo A. Bressan(5), Dudley J. Pennell(4), Robin Murray(4), Michael J. Travis(4), Wendy A. Waddington(4), Elizabeth Prvulovich(3), R H Swanton(3), John M. Walker(3), Peter H. Jarritt(3), Sveto Gacinovic(3), Isaac Marks(3), Dimitris Visvikis(3)